(Reuters) -Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market weight-loss drug Poviztra semaglutide injection in the country, the Indian firm said on
Novo Nordisk and Emcure to Introduce New Weight-Loss Drug in India
Novo Nordisk and Emcure's Partnership
(Reuters) -Novo Nordisk has partnered with India's Emcure Pharmaceuticals to exclusively distribute and market its weight-loss drug under a new brand in the country, the companies said on Monday.
Details of the Agreement
Under the agreement, the Danish drugmaker will sell Poviztra 2.4 milligram (mg) semaglutide injection in India as a separate brand of its blockbuster weight-loss treatment Wegovy.
Market Response and Pricing
Shares of Emcure Pharma rose following the announcement, trading 6.5% higher at 1,451 rupees.
Competitive Landscape in India
Novo Nordisk launched Wegovy in India in June, three months after Eli Lilly introduced its competing weight-loss product Mounjaro in the world's most populous nation.
Wegovy's 2.4 mg dose is priced at 26,015 rupees for a month's supply in India, while pricing for Poviztra was not disclosed.
"This partnership is part of Novo Nordisk India's efforts to ensure its innovative treatments reach a greater number of patients in India," the Danish company said in an exchange filing.
Last month, Eli Lilly also partnered with Cipla to sell its weight-loss drug under a separate brand in India.
(Reporting by Manvi Pant in Bengaluru; Editing by Mrigank Dhaniwala and Sherry Jacob-Phillips)
